# Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

> **NCT04392505** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Oslo University Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Cancer
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Stage III
- NSCLC
- NSCLC, Stage III

## Interventions

- **DRUG:** Durvalumab Injection

## Key facts

- **NCT ID:** NCT04392505
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-11
- **Primary completion:** 2025-05-01
- **Final completion:** 2033-05-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04392505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04392505, "Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04392505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*